A First-Hand Look at India's Pharma Services Sector - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

A First-Hand Look at India's Pharma Services Sector
Indian manufacturers are not a near-term threat to Western CMOs, but may be long term.

Pharmaceutical Technology
Volume 35, Issue 3, pp. 134-136

Formulation CROs face challenges

In addition to the manufacturers, we also visited dedicated contract services companies offering discovery, API process development, and formulation-development services, along with clinical-scale manufacturing. These companies are largely targeting Western bio/pharmaceutical companies as their key clients, although they are finding clients within India as well. The impression left by these companies was decidedly mixed. Some reflected a high level of sophistication and understanding of what Western companies are looking for and expect, and others offered barebones facilities that generally wouldn't pass muster with prospective clients from major bio/pharmaceutical companies.

The performance of these services-only companies varied by service offering. Those offering discovery and process development services appear to be doing quite well while those offering formulation development and early-stage clinical trial material (CTM) services are not as robust. The global bio/pharmaceutical companies began turning to Indian and Chinese CROs for discovery and process chemistry services almost 10 years ago, and several of these companies have emerged as world-class service providers. We visited the Hyderabad campuses of two of industry leaders in chemistry outsourcing, GVK Bio and Aptuit, and came away impressed with the sophistication of their leadership and quality of their facilities and operations.

The challenge for the formulation development companies seems to be two-fold: the local market for CTM is somewhat limited by the fact that bio/pharmaceutical companies cannot conduct first-in-man studies in India, and expenditures for early formulation-development services are so low at most Western companies these days that the expected cost savings from going to India are minimal. Near term, we think those companies are going to have to establish a laboratory presence in the Western markets to capture that early-phase business, with the intention that the products can be transitioned to Indian facilities as the products approach commercialization. Longer term, the formulation-development CROs will benefit as global bio/pharmaceutical companies establish more R&D operations in India and source more of their needs locally.

My overall conclusion is that India is building a base for a strong local contract services industry in the coming years. The threat for Western contract development and manufacturing organizations (CDMOs) and CMOs is small in the near-term, but as global bio/pharmaceutical companies target this fast-growing market, Indian firms will be well-positioned to seize the opportunity.

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report, tel. 703.383.4903, fax 703.383.4905,
, http://www.pharmsource.com/.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here